U.S., March 25 -- ClinicalTrials.gov registry received information related to the study (NCT06892054) titled 'Sotorasib Combined with First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma' on Feb. 05.
Brief Summary: The main objective of this trial is to evaluate the safety and tolerability of sotorasib combined with first-line chemotherapy for advanced pancreatic adenocarcinoma harboring KRAS p.G12C mutation.
Study Start Date: June 30, 2025
Study Type: INTERVENTIONAL
Condition:
Pancreatic Adenocarcinoma
Intervention:
DRUG: Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days)
A minimum of 6 and a maximum of 15 patients will be enrolled to receive first-line chemotherapy (gem/nab-P or mFOLFIRINOX) in combination with sot...